earnings out…

Gilead just put up a nice beat driven by both top line (massive hepatitis C beat) and expense control," Evercore ISI analyst Mark Schoenebaum said in a note to clients.

Excluding one-time items, Gilead earned $2.94 per share in the first quarter, outpacing the average Wall Street estimate of $2.32, according to Thomson Reuters I/B/E/S.

nice along with the BOFI and SWKS reports